|

Bovine rotavirus pentavalent vaccine development in India.

Zade, Jagdish K; Kulkarni, Prasad S; Desai, Sajjad A; Sabale, Rajendra N; Naik, Sameer P; Dhere, Rajeev M.

Vaccine ; 32 Suppl 1: A124-8, 2014 Aug 11.

Article En | MEDLINE | ID: mdl-25091665

A bovine rotavirus pentavalent vaccine (BRV-PV) containing rotavirus human-bovine (UK) reassortant strains of serotype G1, G2, G3, G4 and G9 has been developed by the Serum Institute of India Ltd, in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), USA. The vaccine underwent animal toxicity studies and Phase I and II studies in adults, toddlers and infants. It has been found safe and immunogenic and will undergo a large Phase III study to assess efficacy against severe rotavirus gastroenteritis.

Rotavirus Infections/prevention & control , Rotavirus Vaccines/immunology , Animals , Antibodies, Viral/blood , Cattle , Clinical Trials, Phase I as Topic , Clinical Trials, Phase II as Topic , Gastroenteritis/prevention & control , Gastroenteritis/virology , India , Rabbits , Randomized Controlled Trials as Topic , Rats, Wistar , Reassortant Viruses , Rotavirus , Toxicity Tests , Vaccines, Attenuated/immunology